WO2005089796A1 - Modification chimique specifique de site de peptides derives de gp41 du vih - Google Patents

Modification chimique specifique de site de peptides derives de gp41 du vih Download PDF

Info

Publication number
WO2005089796A1
WO2005089796A1 PCT/US2005/007486 US2005007486W WO2005089796A1 WO 2005089796 A1 WO2005089796 A1 WO 2005089796A1 US 2005007486 W US2005007486 W US 2005007486W WO 2005089796 A1 WO2005089796 A1 WO 2005089796A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
amine
amino acid
peptide
polymer
Prior art date
Application number
PCT/US2005/007486
Other languages
English (en)
Inventor
Brian Bray
Huyi Zhang
Original Assignee
Trimeris, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris, Inc. filed Critical Trimeris, Inc.
Priority to EP05724921A priority Critical patent/EP1734994A1/fr
Priority to JP2007503945A priority patent/JP2007529522A/ja
Priority to CA002556032A priority patent/CA2556032A1/fr
Publication of WO2005089796A1 publication Critical patent/WO2005089796A1/fr
Priority to IL177268A priority patent/IL177268A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to a method for the site-specific chemical modification of an HIV gp41 -derived peptide such that, during peptide synthesis, added is one or more amino acids having an amine group chemically protected with a chemical protecting agent, leaving one or more free amine groups of the synthetic peptide chosen to be unprotected so as to be chemically reactive ("free").
  • the resultant synthetic peptide may then be covalentiy coupled to an amine-reactive polymer in forming a substantially homogeneous conjugate comprised of HIV gp41 -derived peptide to which, in selected and specific site(s) of the synthetic peptide, is covalentiy coupled the polymer.
  • gp120/gp41 the viral envelope glycoprotein complex
  • cellular receptors e.g., CD4 in combination with a chemokine co-receptor such as CCR-5 or CXCR-4
  • induced is a conformational change in the gp120/gp41 complex that allows gp41 to insert into the membrane of the target cell and mediate membrane fusion.
  • FIG.1 is a schematic representation of the generally accepted functional domains of gp41 (note the amino acid sequence numbers may vary slightly depending on the HIV strain).
  • the fusion peptide (fusogenic domain) is believed to be involved in insertion into and disruption of the target cell membrane.
  • the transmembrane domain containing the transmembrane anchor sequence, is located at the C-terminal end of the protein. Between the fusion peptide and transmembrane anchor are two distinct regions, known as heptad repeat (HR) regions, each region having a plurality of heptads.
  • HR heptad repeat
  • the amino acid sequence comprising the HR1 region and the amino acid sequence comprising the HR2 region are each highly conserved regions in the HIV-1 envelope protein.
  • the HR1 region, nearer to the N-terminal end of the protein than the HR2 region, has been generally described as comprising amino acid residues of SEQ ID NO:1 , or polymorphisms thereof (see, e.g., FIG. 2).
  • the HR2 region has been generally described as comprising amino acid residues of SEQ ID NO:2, or polymorphisms thereof (see, e.g., FIG. 3).
  • the HR regions have a plurality of 7 amino " acid residue stretches or "heptads" (the 7 amino acids in each heptad designated “a” through “g"), with a predominance of hydrophobic residues at the first ("a") and fourth ("d") positions, charged residues frequently at the fifth (“e") and seventh ("g") positions, and with the amino acids in the "a" position and "d” position being primary determinants that influence the oligomeric state and strand orientation. It was discovered that peptides derived from the native sequence of either the
  • HR1 region (“HR1 peptides”) or HR2 region (“HR2 peptides”) of HIV gp41 inhibit transmission of HIV to host cells both in in vitro assays and in in vivo clinical studies.
  • HR2 peptides as exemplified by DP178 (also known as T20, enfuvirtide, and Fuzeon® ; SEQ ID NO:3), T651 (SEQ ID NO:4), T649 (SEQ ID NO:5), blocked infection of target cells with potencies of 0.5 ng/ml (EC50 against HIV-1 LA I), 5 ng/ml (IC50; HIV-1 1MB), and 2 ng/ml (IC50; HIV-1 NIB), respectively.
  • PEGylation is the process by which the drug is chemically modified to result in the covalent attachment ("coupling") of one or more PEG molecules to the drug (depending on how many sites are available on the drug to interact with, and be conjugated to PEG).
  • the improved pharmacological and biological properties associated with PEGylation of drugs are well known in the pharmaceutical art.
  • PEGylation can increase therapeutic efficacy by means including, but not limited to, reducing degradation by proteolytic enzymes and thereby increasing drug concentration; increasing the size of the drug to which it is attached, thereby improving drug biodistribution; and shielding antigenic epitopes in reducing immunogenicity where desired.
  • PEG as a linear polyether, has a general structure of: HO-(CH 2 -CH 2 O) n -CH 2 CH 2 -OH where n can typically range from about 10 to about 2000.
  • PEG as a branched polyether, has a general structure of: PEG-T-PEG Z wherein T is a linker or molecular bridge linking the PEG molecules, and Z is the functional group with chemically reactive moiety.
  • PEG modifications in forming PEG derivatives (PEG and PEG derivatives are known in the art as "PEG"), are directed to the end groups ("functionalities") in adding or varying their chemically reactive functionalities to be used to covalentiy attach the PEG molecule to a drug.
  • PEG derivatives are well known in the art. To couple PEG to a drug, typically a functionality of the PEG molecule needs to be activated so as to be chemically reactive.
  • the type and specificity of functionality is based upon the choice of chemically reactive group on the drug to which the PEG molecule is to be coupled.
  • the chemically reactive group is present on an amino acid selected from the group consisting of an internal amino acid having a side chain with a free chemically reactive group (e.g., including, but not limited to, lysine, cysteine, glutamic acid, serine, threonine, and the like), the N-terminal amino acid (having a N-terminal amine group, or a side chain amine group, as a free chemically reactive group), a C-terminal amino acid (having a C-terminal carboxylic acid, or side chain amine group, as a free chemically reactive group), and a combination thereof.
  • an internal amino acid having a side chain with a free chemically reactive group e.g., including, but not limited to, lysine, cysteine, glutamic acid, serine, threonine, and the like
  • a peptide to be coupled to PEG most frequently chosen is the N-terminal amine group ("alpha amine”) of the peptide's N-terminal amino acid, and the epsilon amine group (“epsilon amine”) of a lysine (a lysine found within the amino acid sequence which is not the N-terminal amino acid or the C-terminal amino acid of the peptide) or an epsilon amine group of lysine when the lysine is present in a peptide as a N-terminal amino acid or as a C-terminal amino acid.
  • HIV gp41 there are multiple lysine residues in the amino acid sequences of the HR1 region and the HR2 region (see, e.g., FIGs. 1-3). With respect to HIV gp41 -derived peptide T20 (SEQ ID NO:1 ), for example, there are two internal lysine residues in this 36 amino acid residue peptide. Thus, with a plurality of lysine residues in the amino acid sequence (hence, a plurality of side chain amines (epsilon amines) available to be reactive with activated PEG containing amine-reactive functionality) and an alpha amine, there exists several sites to which the activated PEG with an amine reactive functionality, can be covalentiy coupled.
  • a plurality of lysine residues in the amino acid sequence here, a plurality of side chain amines (epsilon amines) available to be reactive with activated PEG containing amine-reactive functionality
  • an alpha amine there exists several
  • the result of standard PEGylation of such a peptide is a heterogeneous mixture comprised of a population of several conjugates varying in the number of PEG molecules attached and in the sites of attachment. Heterogeneity of such a synthetic peptide- polymer conjugate is often an undesirable result. This is because the pharmacological and/or biological properties associated with PEGylation of peptides can be dependent on factors such as (a) the number of PEG molecules attached to the peptide, and (b) the location of the sites on the peptide to which PEG is coupled. For example, in vitro biological activity of PEGylated human growth hormone-releasing factor depended on both the site and degree of PEGylation.
  • conjugates comprised of an HIV gp41 -derived peptide (containing one or more internal amino acid residues having a side chain amine in its amino acid sequence) and polymer
  • a site-specific modification of the synthetic peptide so that prodgced is a synthetic peptide containing one or more selected amino acids having a side chain amine chemically protected with a chemical protecting agent, and one or more amino acids having an unprotected, free amine available.
  • a polymer may be covalentiy coupled only to a specific site, or specific sites, on the synthetic peptide, as selected by a person performing the synthesis and conjugation.
  • the present invention relates to a method for site-specific chemical modification of an HIV gp41 -derived peptide during synthesis of the peptide, wherein the synthesized peptide has one or more amino acids having a side chain amine.
  • the method comprises incorporating into the peptide, or a fragment thereof, during synthesis, at least one amino acid selected to have its side chain amine chemically reacted with a chemical protecting agent which protects the side chain amine from subsequent chemically reactivity with an amine-reactive functionality; and at least one amino acid having an amine unprotected and free for reacting with an amine-reactive functionality, wherein the free amine is selected from the group consisting of an N-terminal amine, a side chain amine, and a combination thereof.
  • an isolated HIV gp41 -derived peptide having one or more amino acids containing a side chain amine, wherein at least one amino acid has its side chain amine chemically reacted with a chemical protecting agent which protects the side chain amine from subsequent chemically reactivity with an amine-reactive functionality; and at least one amino acid of the synthetic peptide has an amine unprotected and free for reacting with an amine-reactive functionality, wherein the free amine is selected from the group consisting of an N-terminal amine, a side chain amine, and a combination thereof.
  • the present invention relates to a method for producing a substantially homogeneous conjugate comprised of HIV gp41 -derived peptide and polymer, wherein the HIV gp41 -derived peptide has, incorporated into its amino acid sequence during synthesis, one or more amino acids having a side chain amine which has been selected to be blocked by a chemical protecting agent, allowing only the desired (selected) unblocked free amine group(s) of the synthetic peptide to be available for reaction with a polymer containing a amine-reactive functionality, in covalentiy coupling the synthetic peptide to the polymer at only specific site(s) (amino acid position(s) of the synthetic peptide) containing a free amine.
  • the present invention also relates to a substantially - homogeneous conjugate comprised of HIV gp41 -derived peptide and polymer produced according to this method according to the present invention.
  • the present invention also provides a method for site-specific PEGylation of an HIV gp41 -derived peptide, wherein PEG is covalentiy coupled in a site-specific manner to an HIV gp41 -derived peptide.
  • the HIV gp41 -derived peptide having had incorporated into its amino acid sequence at selected amino acid positions during synthesis, one or more amine groups (e.g., one or more of: an alpha amine or an epsilon amine(s)) which is blocked with a chemical protecting agent from chemically reactive with amine-reactive functionality of PEG during PEGylation, thereby leaving available for PEGylation only the free amine group(s) in selected amino acid positions (through chemical modification) of the synthetic peptide to be covalentiy coupled to PEG.
  • amine groups e.g., one or more of: an alpha amine or an epsilon amine(s)
  • a substantially homogeneous composition comprising a PEGylated HIV gp41 -derived peptide containing one or more (as selected in performing the method of site-specific chemical modification) amine groups conjugated to PEG.
  • the methods of the present invention may further comprise removal of the chemical protecting agent (in a "deprotection" step) in providing a substantially homogeneous conjugate comprised of an HIV gp41-derived peptide which is conjugated to a polymer at only specific site(s) of the synthetic peptide, as selected in performance of the method of the present invention (e.g., through use of chemical protection), wherein such conjugate retains substantial anti-HIV activity (as compared to the anti-HIV activity of the synthetic peptide when not conjugated to polymer).
  • a substantially homogeneous conjugate comprised of an HIV gp41-derived peptide which is conjugated to a polymer at only specific site(s) of the synthetic peptide, as selected in performance of the method of the present invention (e.g., through use of chemical protection), wherein such conjugate retains substantial anti-HIV activity (as compared to the anti-HIV activity of the synthetic peptide when not conjugated to polymer).
  • the present invention also provides for a method of treating HIV infection (preferably, HIV-1 infection) comprising administering to an HIV-infected individual a pharmaceutical composition comprising a substantially homogeneous conjugate comprised of an HIV gp41-derived synthetic peptide site-specifically coupled (e.g., conjugated) to polymer.
  • a pharmaceutical composition comprising a substantially homogeneous conjugate comprised of an HIV gp41-derived synthetic peptide site-specifically coupled (e.g., conjugated) to polymer.
  • the pharmaceutical composition is in an amount effective to inhibit transmission of HIV to a target cell, and/or in an amount effective to inhibit gp41 -mediated fusion of HIV to a target cell.
  • Also provided is a method for inhibition of transmission of HIV to a cell comprising contacting the virus in the presence of a cell with the substantially homogeneous conjugate of polymer and synthetic peptide according to the present invention in an amount effective to inhibit infection of the cell by HIV. Additionally, provided is a method for inhibition of transmission of HIV to a cell, comprising adding to the virus and the cell an amount of the substantially homogeneous conjugate of polymer and synthetic peptide according to the present invention effective to inhibit infection of the cell by HIV.
  • Also provided is a method for inhibiting HIV fusion e.g., a process by which HIV gp41 mediates fusion between the viral membrane and cell membrane during infection by HIV of a target cell
  • a method for inhibiting HIV fusion comprising contacting the virus in the presence of a cell with an amount of the substantially homogeneous conjugate of polymer and synthetic peptide according to the present invention effective to inhibit HIV fusion.
  • These methods may be used to treat HIV-infected individuals.
  • the present invention also provides the use of a substantially homogeneous conjugate of polymer and synthetic peptide, produced by the method according to the present invention, in the manufacture of a medicament for use with in therapy of HIV infection (e.g., used in a method of inhibiting transmission of HIV, a method of inhibiting HIV fusion, or a method of treating HIV infection), as described herein.
  • the medicament is preferably in the form of a pharmaceutical composition comprising a substantially homogeneous conjugate of polymer and synthetic peptide according to the present invention together with a pharmaceutically acceptable carrier.
  • FIG. 1 is a schematic of HIV-1 gp41 showing the heptad repeat 1 region (HR1 ) and heptad repeat 2 region (HR2) along with other functional regions of gp41.
  • HR1 heptad repeat 1 region
  • HR2 heptad repeat 2 region
  • FIG. 2 shows a comparison of the sequences contained within the HR1 region of HIV-1 gp41 for purposes of illustration, and not limitation, as determined from various laboratory strains and clinical isolates, wherein illustrated are some of the variations in amino acid sequence (e.g., polymorphisms), as indicated by the single letter amino acid code.
  • FIG. 1 is a schematic of HIV-1 gp41 showing the heptad repeat 1 region (HR1 ) and heptad repeat 2 region (HR2) along with other functional regions of gp41.
  • Exemplary amino acid sequences corresponding to HR1 and HR2, and the amino acid position numbering, are shown for purposes of illustration and in relation to gp160, strain HIVm B
  • FIG. 3 shows a comparison of the sequences contained within the HR2 region of HIV-1 gp41 for purposes of illustration, and not limitation, as determined from various laboratory strains and clinical isolates, wherein illustrated are some of the variations in amino acid sequence (e.g., polymorphisms), as indicated by the single letter amino acid code.
  • FIG. 3 shows a comparison of the sequences contained within the HR2 region of HIV-1 gp41 for purposes of illustration, and not limitation, as determined from various laboratory strains and clinical isolates, wherein illustrated are some of the variations in amino acid sequence (e.g., polymorphisms), as indicated by the single letter amino acid code.
  • FIG. 4 is a schematic showing synthesis of an HIV gp41-derived peptide using a fragment condensation approach, wherein: the numbers represent respective amino acid positions relative to the synthesized HIV gp41 -derived peptide; "K” represents a lysine internal to the sequence of the synthetic peptide, or to a fragment used in the synthesis of the synthetic peptide; "Ac” represents acetylation of the N-terminus; and "NH” represents amidation of the C-terminus.
  • FIG. 5 is a schematic showing synthesis of modified HIV gp41 -derived peptide, and a conjugate of polymer and synthetic peptide, according to the present invention, wherein: the numbers represent respective amino acid positions relative to the synthesized HIV gp41 -derived peptide; "K” represents a lysine internal to the sequence of the synthetic peptide, or to a fragment used in the synthesis of the synthetic peptide; "Ac” represents acetylation of the N-terminus; “NH” represents amidation of the C-terminus; “X” represents a chemical protecting agent which is coupled to an epsilon amine of a selected amino acid in selectively blocking the amino acid side chain from further chemical reactivity; and “ ⁇ ” represents a polymer which has specificity for chemically coupling with a free amine group, and becomes conjugated to a free amine of an amino acid which is not coupled to a chemical protecting agent in a site-specific chemical modification.
  • an isolated HIV gp41 -derived peptide having at least one amine group e.g., epsilon amine of the lysine residue at amino acid position 18
  • a chemical protecting agent e.g., a substantially homogeneous conjugate comprised of HIV gp41 -derived peptide and polymer, with polymer conjugated site-specifically to the synthetic peptide (e.g., at the epsilon amine of the lysine residue at amino acid position 28).
  • FIG. 6 is a schematic showing synthesis of modified HIV gp41 -derived peptide, and a conjugate of polymer and synthetic peptide, according to the present invention, wherein: the numbers represent respective amino acid positions relative to the synthesized HIV gp41 -derived peptide; "K” represents a lysine internal to the sequence of the synthetic peptide, or to the fragment used in .the synthesis of the synthetic peptide; "Ac” represents acetylation of the N-terminus; “NH” represents amidation of the C-terminus; “X” represents a chemical protecting agent which is coupled to an epsilon amine in selectively blocking the amino acid side chain from further chemical reactivity; and “ ⁇ ” represents a polymer which is conjugated to an amine of an amino acid which is not coupled to a chemical protecting agent in a site-specific chemical modification.
  • an isolated HIV gp41-derived peptide having at least one amine group e.g., epsilon amine of the lysine residue at amino acid position 28
  • a chemical protecting agent e.g., a substantially homogeneous conjugate comprised of HIV gp41- derived peptide and polymer, with polymer conjugated site-specifically to the synthetic peptide (e.g., at the epsilon amine of the lysine residue at amino acid position 18).
  • target cell when used herein for purposes of the specification and claims, means a cell capable of being infected by HIV.
  • the cell is a human cell or are human cells; and more preferably, human cells capable of being infected by HIV via a process including membrane fusion.
  • pharmaceutically acceptable carrier when used herein for purposes of the specification and claims, means a carrier medium that does not significantly alter the biological activity of the active ingredient (e.g., a conjugate of polymer and synthetic peptide according to the present invention) to which it is added.
  • a pharmaceutically acceptable carrier includes, but is not limited to, one or more of water, buffered water, saline, 0.3% glycine, aqueous alcohols, isotonic aqueous solution; and may further include one or more substances such as glycerol, oils, salts such as sodium, potassium, magnesium and ammonium, phosphonates, carbonate esters, fatty acids, saccharides (e.g., mannitol), polysaccharides, excipients, and preservatives and/or stabilizers (to increase shelf-life or as necessary and suitable for manufacture and distribution of the composition).
  • the pharmaceutically acceptable carrier is suitable for intravenous, intramuscular, subcutaneous or parenteral administration.
  • amino acid is meant, for purposes of the specification and claims and in reference to the synthetic peptides used in the present invention, to refer to a molecule that has at least one free amine group and at least one free carboxyl group.
  • the amino acid may have more than one free amine group, or more than one free carboxyl group, or may further comprise one or more free chemical reactive groups other than an amine or a carboxyl group (e.g., a hydroxyl, a sulfhydryl, etc.).
  • the amino acid may be a naturally occurring amino acid (e.g., L-amino acid), a non-naturally occurring amino acid (e.g., D-amino acid), a synthetic amino acid, a modified amino acid, an amino acid derivative, an amino acid precursor, and a conservative substitution.
  • L-amino acid a naturally occurring amino acid
  • D-amino acid a non-naturally occurring amino acid
  • synthetic amino acid a modified amino acid
  • an amino acid derivative e.g., an amino acid precursor
  • conservative substitution e.g., amino acid derivative of amino acid
  • One skilled in the art would know that the choice of amino acids incorporated into a peptide will depend, in part, on the specific physical, chemical or biological characteristics required of the antiviral peptide. Such characteristics are determined, in part, by determination of structure and function (e.g., antiviral activity; as described herein in more detail).
  • amino acids in a synthetic peptide may be comprised of one or more of naturally occurring (L)-amino acid and non-naturally occurring (D)-amino acid.
  • a preferred amino acid may be used to the exclusion of amino acids other than the preferred amino acid.
  • a “conservative substitution”, in relation to amino acid sequence of a synthetic peptide Used in the present invention, is a term used hereinafter for the purposes of the specification and claims to mean one or more amino acids substitution in the sequence of the synthetic peptide such that its biological activity is substantially unchanged (e.g., if the peptide inhibits HIV gp41 -mediated fusion at a concentration in the nanomolar range before the substitution, after the substitution inhibition of HIV gp41-mediated fusion is still observed in the nanomolar range).
  • conservative substitution is defined by aforementioned function, and includes substitutions of amino acids having substantially the same charge, size, hydrophilicity, and/or aromaticity as the amino acid replaced.
  • substitutions are known to those of ordinary skill in the art to include, but are not limited to, glycine-alanine-valine; isoleucine-leucine; tryptophan-tyrosine; aspartic acid-glutamic acid; arginine-lysine; asparagine-glutamine; and serine-threonine.
  • a conserved substitution is known in the art to also include substituting lysine with ornithine, in providing a free amine group (e.g., epsilon amine).
  • substitutions may also comprise polymorphisms at the various amino acid positions along the relevant HR region (HR1 or HR2) of gp41 found in any one or more of various clades, laboratory strains, or clinical isolates of HIV, which are readily available from public databases and are well known in the art (see also, FIGs. 2 & 3, as illustrative examples).
  • polymer when used herein for purposes of the specification and claims, means a polymeric molecule which:(a) is employed in pharmaceutical applications to improve the pharmacological and/or biological properties when conjugated to a drug (and therefore is substantially nontoxic and substantially water soluble); (b) has one or more functionalities which by itself, and/or after activation to become chemically reactive, can be used to covalentiy couple to a free amine of the drug (e.g., a synthetic peptide) in forming a drug-polymer conjugate.
  • the polymer preferably has an amine-reactive functionality for covalentiy coupling to synthetic peptide.
  • a polymer may include, but is not limited to, polylysines or poly(D-L-alanine)-poly(L-lysine)s, or polyols.
  • a preferred polyol comprises a water-soluble poly(alkylene oxide) polymer, and can have a linear or branched chain.
  • polyol is preferably a water-soluble, polyalcohol which may include, but is not limited to, polyethylene glycol ("PEG”), polypropylene glycol ("PPG”), diethylene glycol, triethylene glycol, ethylene glycol, dipropylene glycol, copolymers comprising PPG (e.g., ethylene glycol/PPG), copolymers comprising PEG (e.g., PEG/PPG), mPEG (monomethoxy-poly(ethylene) glycol), and the like.
  • PEG polyethylene glycol
  • PPG polypropylene glycol
  • a polyol encompasses both homopolymers and copolymers, and further may have a structure comprising a branched structure or linear structure as known to those skilled in the art.
  • the polymer is substantially non-toxic when used for in vivo applications in individuals.
  • the polymer has a molecular weight in the range between about 200 daltons to about 40,000 daltons; and in a more preferred embodiment, the polymer has a molecular weight range between about 400 daltons to about 10,000 daltons.
  • a preferred polymer for application in the present invention comprises a polyethylene glycol ("PEG"), and a more preferred polymer for application in the present invention comprises a polyethylene glycol having a molecular weight range, wherein the molecular weight range is no less than about 400 daltons and is no more than about 20,000 daltons.
  • PEG poly(ethylene glycol)
  • end groups or chemically reactive functional groups to be used to covalentiy attach the PEG molecule to a drug.
  • PEGs are well known in the art.
  • a preferred PEG, for use in coupling to one or more unprotected amine groups of the synthetic peptide in accordance with the present invention has a chemically reactive group (e.g., "functionality") which can be used covalentiy couple PEG to the to one or more unprotected amine groups.
  • PEG may include but is not limited to, PEG-tresylate, heterobifunctional PEG, PEG dichlorotriazine, PEG succinimidyl carbonate, PEG benzotriazole carbonate, PEG p-nitrophenyl carbonate, PEG trichlorophenyl carbonate, PEG carbonylimidazole, PEG succinimidyl succinate, mPEG succinimidyl propionate, mPEG succinimidyl butanoate, PEG butyraldehyde, mPEG-propionaldehyde, PEG aldehyde, PEG-acetaldehyde, PEG acetaldehyde diethyl acetal, PEG carboxylic acid, mPEG phenyl ether succinimidyl carbonates, mPEG benzamide succinimidyl carbonates, PEG thioester, linear PEG, branched PEG, and linear forked PEG.
  • a preferred polymer may be applied to the present invention to the exclusion of a polymer other than the preferred polymer.
  • synthetic peptide and "HIV gp41 -derived peptide” are used synonymously herein, in relation to a peptide employed in the present invention, and for the purposes of the specification and claims, to mean a peptide (a) comprising an amino acid sequence of no less than about 15 amino acids and no more than about 60 amino acid residues in length, and comprises at least a portion of the amino acid sequence (preferably, at least 9 contiguous amino acids) contained in either the HR1 region or HR2 region of gp41 of HIV (more preferably of HIV-1 ); and (b) capable of inhibiting transmission of HIV to a target cell (preferably, by complexing to an HR region of HIV-1 gp41 and inhibiting fusion between HIV-1 and a target cell), as can be determined by assessing antiviral activity in vitro and/or in vivo, as will be described in more detail herein.
  • the synthetic peptide employed in the present invention may comprise a sequence of no less than 28 amino acids and no more than about 51 amino acids in length, and even more preferably no less than about 36 amino acids and no more than about 51 amino acids in length.
  • isolated when used in reference to a synthetic peptide means that it is substantially free of components which have not become part of the integral structure of the peptide itself; e.g., such as substantially free of chemical precursors or other chemicals when chemically synthesized, produced, or modified using biological, biochemical, or chemical processes.
  • the synthetic peptide may comprise, in it's amino acid sequence, one or more conservative substitutions and/or one or polymorphisms found in the sequence of the relevant region of the HIV gp41 , or may comprise one or more amino acid substitutions which are added to stabilize helix structure and/or affect oligomerization; provided that it retains substantial antiviral activity against HIV-1 (e.g., an IC50 in the picomolar to micromolar range).
  • the following are illustrative examples of HIV gp41 -derived peptides that can be site-specifically conjugated to polymer in accordance with the present invention.
  • a preferred synthetic peptide may be used in the present invention to the exclusion of a synthetic peptide other than the preferred synthetic peptide.
  • a lysine in the amino acid sequence of a synthetic peptide may be substituted with another amino acid (naturally occurring or not naturally occurring) having a side chain with a free amino group (e.g., epsilon amine).
  • Ornithine is an illustrative example of such amino acid that may be used to substitute a lysine.
  • the synthetic peptide comprises a contiguous sequence of at least 15 amino acid residues in the amino acid sequence of SEQ ID NO:1 , or polymorphisms thereof, as key determinants in this portion of the HR1 region (e.g., such as, noted by single letter amino acid designation, NNLLRAIEAQQHLLQLTVWG IKQLQARI LAVERYLKD which is amino acid residue 18 to amino acid residue 54 of SEQ ID NO:1) have been found to influence structure, and biochemical and antiviral parameters described herein.
  • a synthetic peptide derived from the HR-1 region of HIV gp41 and as containing the amino acids found in the native sequence of this region, are illustrated as having amino acid sequences of SEQ ID NOs:7-22, and may further comprise an amino acid sequence having at least 95% identity, and more preferably having at least 90% identity, with any one or more of SEQ ID NOs:6-22.
  • a synthetic peptide derived from the HR1 region of HIV gp41 contains one or more amino acid substitutions (e.g., as compared to the amino acid sequence of SEQ ID NO:1 ) which preferably enables the synthetic peptide to self-assemble into trimers (e.g., a trimer being comprised of three molecules of synthetic peptide), as disclosed in more detail in co- pending application published as U.S. 20040076637.
  • Examples of a synthetic peptide derived from the HR-1 region of HIV gp41 and which further comprises one or more amino acid substitutions which enable the synthetic peptide to self-assemble into trimers are illustrated as having amino acid sequences of SEQ ID NOs:23-36, and may further comprise an amino acid sequence having at least 95% identity, and more preferably having at least 90% identity, with any one or more of SEQ ID NOs: 23-36.
  • such synthetic peptides have one or more lysine residues internal to this portion of the HR1 region, one or more of which may be chosen to be left unprotected (i.e., its side chain reactive group is not chosen to be coupled to the chemical protecting agent), or may be chosen to be chemically protected, in the site-specific chemical modification according to the present invention.
  • the synthetic peptide comprises a contiguous sequence of at least amino acid residues 43 to 51 of SEQ ID NO:2 (e.g., QQEKNEQEL), or polymorphisms thereof, as key determinants in this portion of the HR2 region have been found to influence biochemical and antiviral parameters described herein. Note there is one internal lysine residue in this sequence.
  • Illustrative synthetic peptides derived from the HR2 region include, but are not limited to peptides having the amino acid sequences shown in SEQ ID NOs: 3, 4, 5, 37 to 63, and 175, and may further comprise an amino acid sequence having at least 95% identity, and more preferably having at least 90% identity, with any one or more of SEQ ID NOs:3, 4, 5, 37 to 63, and 175.
  • synthetic peptides have one or more internal lysine residues (and/or in the case of SEQ ID NOs. 34, 39, 48, and 175 at the carboxy terminus), one or more of which may be chosen to be left unprotected, or may be chosen to be chemically protected, in the site-specific chemical modification according to the present invention.
  • a synthetic peptide derived from the HR2 region of HIV gp41 contains one or more amino acid substitutions (e.g., as compared to a relative portion of the amino acid sequence of SEQ ID NO:2) which preferably promotes the helicity and/or helix stability of the synthetic peptide ("helix stabilized peptide") in imparting improved biological activity, as disclosed in more detail in co-pending application PCT/US04/42918.
  • helix stabilized synthetic peptides are illustrated as having amino acid sequences of SEQ ID NOs:64-92, and 113- 174, and may further comprise an amin ⁇ acid sequence having at least 95% identity, and more preferably having at least 90% identity, with any one or more of SEQ ID NOs: 64-92 and 113-174.
  • Other examples of peptides designed for improved helicity and derived from the HR2 region of HIV gp41 may include SEQ ID NOs: 93-95.
  • the synthetic peptide may comprise a "hybrid" peptide comprising amino acid sequences derived from one or more of HIV-1 , HIV-2, and SIV fusion proteins (see, e.g., U.S. Patent No. 6,258,782).
  • hybrid synthetic peptide examples include having amino acid sequences of SEQ ID NOs:96 to112, and may further comprise an amino acid sequence having at least 95% identity, and more preferably having at least 90% identity, with any one or more of SEQ ID NOs:96 to112. Note that such illustrated examples of hybrid synthetic peptides have at least two internal lysine residues, one or more of which may be chosen to be left unprotected, or chosen to be chemically protected, in the site-specific chemical modification according to the present invention.
  • a Reference Sequence may be a synthetic peptide according to any one of SEQ ID NOs: 1-175, and a Compared Sequence is an HIV gp41 -derived peptide which is compared to the Reference Sequence, in determining an amino acid sequence having at least 95% identity with any one or more of the amino acid sequences of SEQ ID NOs: 1-175.
  • chemical protecting agent when used herein for purposes of the specification and claims, means a chemical moiety that: (a) is chemically reactive with a free amine of an amino acid, thereby blocking ("chemically protecting") the amine from reacting with a polymer having a functionality that is amine-reactive; (b) can withstand (e.g., remains chemically reacted with the amine which it is chemically protecting) a deprotection step known to those skilled in the art for removing tBU (t-butyl), Fmoc (9- fluorenylmethoxycarbonyl), Boc (tert-butyloxycarbonyl), or trt (triphenylmethyl(trityl)) from an amino acid; and (c) can be subsequently removed from the amine of the amino acid to which it is chemically reacted, so that the amine becomes unprotected and free for chemical reactivity with an amine-reactive functionality.
  • the chemical protecting agent can withstand removal of Fmoc or Boc from a peptide by reagents typically used in the art for such deprotection, including, for example, one or more of: 20% piperdine, 2% DBU (1 ,8-diazabicyclo[5,4,0]undec-7-ene), 50% to 90% trifluoroacetic acid, a quartenary amine (such as tetrabutyl ammonium fluoride), or an inorganic base such as potassium carbonate.
  • reagents typically used in the art for such deprotection including, for example, one or more of: 20% piperdine, 2% DBU (1 ,8-diazabicyclo[5,4,0]undec-7-ene), 50% to 90% trifluoroacetic acid, a quartenary amine (such as tetrabutyl ammonium fluoride), or an inorganic base such as potassium carbonate.
  • the chemical protecting agent can remain stable (reacted with the amine group) until it is desired to remove the chemical protecting agent, and then the chemical protecting agent is removed in a subsequent, and separate deprotection step (e.g., using 2% hydrazine or other suitable reagent) in yielding a free amine.
  • Such chemical protecting agents are known in the art to include, but are not limited to, 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl ("Dde”), 1 -(4,4-dimethyl-2,6-dioxocyclohex-1 -ylidene)-3-methylbutyl (ivDde), allyloxycarbonyl ("Alloc”), benzyloxycarbonyl (“Cbz”), and 2-chlorobenzyloxycarbonyl ("2- Cl-Z”).
  • the free amine group reacting with the chemical protecting agent is an N-terminal amine of an N-terminal amino acid, or an amine group of a side chain (e.g., epsilon amine) of an amino acid (whether such amino acid is the N- terminal amino acid, a C-terminal amino acid, or an internal amino acid), or a combination thereof, as determined by the site-specific chemical modification.
  • the chemical protecting agent is stable to amine bases to which Fmoc, Boc, tBu, trt, or the like are labile.
  • substantially homogeneous when used herein for purposes of the specification and claims and in reference to a conjugate comprised of an HIV gp41- derived peptide coupled to a polymer produced according to the present invention, means that at least 90%, and more preferably at least 95%, of the resultant conjugate produced contains the synthetic peptide site-specifically coupled to the polymer as intended (i.e., as a single species) by an orthogonal protection strategy employed (as described in more detail in Example 5 herein), according to the method of the present invention.
  • the conjugate may be further purified using separation technology including, but not limited to, chromatographic techniques known in the art.
  • the present invention provides a method for site-specific chemical modification of an HIV gp41 -derived peptide, and provides an isolated HIV gp41 -derived peptide containing at least one side chain amine chemically protected, and containing at least one amine (e.g., N-terminal amino acid alpha amine, one or more side chain amines), or a combination thereof) unprotected and free for reactivity with an amine-reactive functionality.
  • at least one amine e.g., N-terminal amino acid alpha amine, one or more side chain amines
  • the isolated HIV gp41 -derived peptide may then be conjugated (covalentiy coupled) to a polymer at a site-specific location (i.e., at a particular amino acid position, in the synthetic peptide, having a free amine) which is selected (by intentionally not protecting it with a chemical protecting agent) to be coupled to the polymer.
  • a site-specific location i.e., at a particular amino acid position, in the synthetic peptide, having a free amine
  • the coupling of the polymer to the synthetic peptide is via one or more free amine groups of the synthetic peptide available for chemical reaction with a polymer having a functionality which is amine-reactive.
  • one molecule of polymer is covalentiy coupled to an amino acid which is selected to have a free amine in producing a substantially homogeneous conjugate comprised of polymer and HIV gp41 -derived peptide.
  • an isolated HIV gp41- derived peptide produced by a method according to the present invention and a substantially homogeneous conjugate comprised of polymer-synthetic peptide according to the present invention, by using an exemplary HIV gp41 -derived peptide known as T20 (SEQ ID NO:3).
  • Schematic 1 The synthetic peptide, being unmodified at the N-terminus after synthesis, has 3 free amine ("NH2") groups available for coupling to a polymer having an amine reactive functional group: the N-terminal amino acid alpha amine, and two internal lysine residues (labeled Ki and K 2 for ease of description), each with a side chain having an epsilon amine.
  • NH2 free amine
  • Schematic 2 The synthetic peptide shown in schematic 1 is conjugated to a polymer (" ⁇ ") having an amine reactive functionality for coupling to the synthetic peptide.
  • ⁇ polymer having an amine reactive functionality for coupling to the synthetic peptide.
  • Schematic 3 For illustration purposes, only the free amine of internal lysine residue "Ki" is selected to be free for chemical reactivity with an amine reactive functionality.
  • the synthetic peptide is synthesized to incorporate amino acids, having amine groups desired to be blocked from reactivity with the polymer, protected by a chemical protecting agent ("X") in forming an isolated HIV gp41 -derived peptide having at least one amino acid with its side chain amine chemically protected (schematic 3A); polymer is then conjugated to such HIV gp41 -derived peptide (schematic 3B) at the only amino acid having a free amine (lysine residue Ki); and the chemical protecting agent is subsequently removed from amino acids to which it was chemically reacted, in yielding a substantially homogeneous conjugate (schematic 3C).
  • X chemical protecting agent
  • Synthetic peptides may typically be, and have been, synthesized by linear synthesis on a peptide synthesizer using standard solid-phase synthesis techniques and using standard Fmoc peptide chemistry or other standard peptide chemistry.
  • solid phase synthesis or other standard peptide chemistry may be used to synthesize the synthetic peptide, wherein a chemically protected amino acid (e.g., an amino acid having its side chain amine chemically protected as described herein) may be added in the desired amino acid position at the point in synthesis where such amino acid is incorporated into the chain of amino acids to produce the synthetic peptide (as illustrated in Example 6 herein).
  • the HIV gp41 -derived peptide to undergo site- specific chemical modification is synthesized using a fragment condensation approach (see, e.g., FIGs. 4-6), as described in more detail in Example 5 herein. Briefly, 2 or more fragments, each fragment containing amino acid sequence found in a respective portion of the synthetic peptide, is synthesized. In the synthesis of a fragment, if desired, incorporated may be an amino acid having its free amine (e.g., side chain amine) chemically protected by a chemical protecting agent. The fragments are then assembled (covalentiy coupled together in a manner and order) such that the synthetic peptide is produced (with the proper amino acid sequence).
  • a fragment condensation approach see, e.g., FIGs. 4-6, as described in more detail in Example 5 herein. Briefly, 2 or more fragments, each fragment containing amino acid sequence found in a respective portion of the synthetic peptide, is synthesized. In the synthesis of a fragment, if desired, incorporated may
  • T20 ' (SEQ ID NO:3) was synthesized by fragment condensation approach, as previously described in more detail (see, e.g., U.S. Patent No. 6,015,881). Briefly, and as summarized in FIG. 4, fragments to be assembled into the synthetic peptide are first synthesized.
  • a fragment comprising the first 16 amino acids of SEQ ID NO:3 was synthesized by standard solid phase synthesis (using a super acid sensitive resin), with acetylation ("Ac") of the N-terminus while having a hydroxyl group (-OH) at the C-terminus.
  • a fragment comprising amino acids 17-26 of SEQ ID NO:3 was synthesized by standard solid phase synthesis with Fmoc at the N- terminus, and -OH at the C-terminus.
  • a fragment comprising amino acids 27-35 of SEQ ID NO:3 was synthesized by standard solid phase synthesis with Fmoc at the N-terminus, and -OH at the C-terminus. As shown in FIG. 4, the fragment comprising amino acids 27-35 of SEQ ID NO:3 is chemically coupled to amino acid 36 in solution phase to result in a fragment comprising amino acids 27-36 with amidation of the C-terminus.
  • the fragment of amino acids.17-26 of SEQ ID NO:3 was chemically coupled with the fragment of amino acids 27-36 of SEQ ID NO:3 (after removal of Fmoc from the N- terminal amino acid 27).
  • the resulting amino acid sequence having amino acids 17-36 of SEQ ID NO:3 was chemically coupled with the fragment comprising amino acids 1-16 of SEQ ID NO:3 (after removal of Fmoc from the N-terminal amino acid 17) in forming a synthetic peptide comprising the amino acid sequence of SEQ ID NO:3.
  • the synthetic peptide was deprotected/ decarboxylated (to remove tBU, trt, and Boc used in the synthesis of each fragment) with a deprotection step using a cocktail of trifluoracetic acid/dithiothrietol/water (volume percent:90/5/5) at 30 degrees C, for 5 to 6 hours with stirring; and then purified using reverse-phase high performance liquid chromatography. Peptide identity was confirmed with electrospray mass spectrometry.
  • EXAMPLE 2 Illustrated is one embodiment of a method for site specific chemical modification of HIV gp41 -derived peptide which may be used to produce (a) an isolated HIV gp41- derived peptide having a side chain amine group of one or more of its internal amino acids chemically protected; and (b) a substantially homogeneous conjugate comprised of HIV gp41 -derived peptide and polymer.
  • incorporated into a synthetic peptide (or a fragment thereof if a fragment assembly approach is used) during synthesis are: one or more amino acids having its side chain amine blocked by a chemical protecting agent from subsequent chemical reactivity with an amine-reactive functionality; and one or more amino acids having an amine (e.g., selected from the group consisting of N-terminal alpha amine, one or more epsilon amines, and a combination thereof) unprotected, and free for chemical reactivity with an amine-reactive functionality.
  • an amine e.g., selected from the group consisting of N-terminal alpha amine, one or more epsilon amines, and a combination thereof
  • An isolated synthetic peptide produced by this method for site-specific chemical modification can then be covalentiy coupled to polymer, in producing a substantially homogeneous conjugate, by chemically reacting the unprotected ("free") amine group(s) of the synthetic peptide to the amine-reactive functionality of a polymer.
  • T20 SEQ ID NO:3
  • K18 an amino acid with a side chain amine
  • K28 lysine residue at amino acid position 28
  • T20 (SEQ ID NO:3) was synthesized using the fragment condensation approach previously described in Example 1 herein. Briefly, and as summarized in FIG. 5, a fragment comprising the first 16 amino acids of SEQ ID NO:3 was synthesized by standard solid phase synthesis with the N-terminal amine of amino acid residue 1 ("Y") being acetylated ("Ac").
  • a fragment comprising amino acids 17-26 of SEQ ID NO:3 was synthesized by standard solid phase synthesis using Fmoc-Lys-(ivDde) as amino acid residue 18, so that the chemical protecting agent ivDde ("X" in FIG. 5) blocks the epsilon amine group of K18 from reacting subsequently with an amine reactive functionality.
  • a fragment comprising amino acids 27-35 of SEQ ID NO:3 was synthesized by standard solid phase synthesis, and chemically coupled to amino acid 36 in solution phase in forming a fragment comprising amino acids 27-36 of SEQ ID NO:3.
  • the fragment comprising amino acids 17-26 of SEQ ID NO:3 was chemically coupled with the fragment of amino acids 27-36 of SEQ ID NO:3 (containing a lysine at position 28 ("K28") with a free epsilon amine).
  • the resulting amino acid sequence comprising amino acids 17-36 of SEQ ID NO:3 was combined with the fragment comprising amino acids 1-16 of SEQ ID NO:3 in forming an isolated HIV gp41 -derived peptide having the amino acid sequence of SEQ ID NO:3 and containing at least one amino acid having its side chain amine group chemically protected (blocked from subsequent chemical reactivity with an amine-reactive functionality) by a chemical protecting agent.
  • the synthetic peptide (SEQ ID NO:3) was deprotected to remove protecting groups trt, Boc, and tBu used in standard solid phase synthesis as described in more detail in Example 1 herein (while K18 remains chemically protected); decarboxylated; and then purified using reverse-phase high performance liquid chromatography.
  • the isolated HIV gp41 -derived peptide was then used for coupling a polymer site-specifically to the free epsilon amine of K28 of SEQ ID NO:3.
  • mPEG succinimidyl propionate (mPEG -SPA) was chosen as the exemplary polymer to conjugate to T20 (SEQ ID NO:3).
  • T20 SEQ ID NO:3 with ivDde on epsilon amine group of K18 (9.0 mg, 2.0 ⁇ mol) was dissolved in dimethyl formamide (DMF)(0.3 ml).
  • DIEA Diisopropylethylamine
  • the reaction mixture was diluted by water (6.5ml) to make the final concentration of DMF at 20%, and then filtered through syringe filter (0.45 ⁇ m, 2ml).
  • HPLC purification was carried out on polystyrene/ divinylbenzene column (PRLP-S, 300A, 10 ⁇ m, 250 * 21.2mm) with acetonitrile-water-0.1 % trifluoroacidic acid buffer as eluent.
  • PRLP-S polystyrene/ divinylbenzene column
  • the collected fractions were checked by HPLC with both UV and ELS detectors. The pure fractions were pooled together and lyophilized for two days.
  • the desired conjugate a substantially homogeneous conjugate comprised of 5K-PEG-T20 at K28, was obtained as fluffy white solid (5.5mg) after lyophilization.
  • the alpha amine of the N-terminal amino acid of SEQ ID NO:1 was not acetylated, but instead was protected with an Fmoc group.
  • the process of synthetic peptide synthesis and conjugation to polymer was performed as provided in this Example 2.
  • the resultant substantially homogeneous conjugate comprised 5K-PEG-T20 at K28, except that the T20 (SEQ ID NO:3) of the conjugate contained a free alpha amine at the N-terminal amino acid (Y).
  • EXAMPLE 3 Illustrated is another embodiment of a method for site specific chemical modification of HIV gp41 -derived peptide which may be used to produce (a) an isolated HIV gp41 -derived peptide having one or more internal amino acids with a side chain amine chemically protected; and (b) a substantially homogeneous conjugate comprised of
  • T20 (SEQ ID NO:3) was selected as the exemplary synthetic peptide, and the lysine residue at amino acid position 28 ("K28") was chosen to be chemically protected by a site-specific chemical modification, leaving lysine residue at amino acid position 18 ("K18") as the internal amino acid to be free for subsequent coupling to a polymer via the lysine side chain amine and an amine-reactive functionality of a polymer.
  • K28 lysine residue at amino acid position 28
  • K18 lysine residue at amino acid position 18
  • FIG. 6 T20 (SEQ ID NO:3) was synthesized using the fragment condensation approach essentially as described in Example 1 herein. Briefly, and as summarized in FIG.
  • a fragment of SEQ ID NO:3 comprising the first 16 amino acids was synthesized by standard solid phase synthesis with the N-terminal amine of amino acid residue 1 (Tyr) being acetylated ("Ac").
  • a fragment of SEQ ID NO:3 comprising amino acids 17-26 was synthesized by standard solid phase synthesis.
  • a fragment of SEQ ID NO:3 comprising amino acids 27-35 was synthesized by standard solid phase synthesis using Fmoc-Lys-(ivDde) as amino acid residue 28 ("K28”), so that the chemical protecting agent ivDde (“X” in FIG. 6) blocks the epsilon amine group of K28 from subsequent chemical reactivity with an amine reactive functional group.
  • the latter fragment was coupled to amino acid 36 in solution phase to form a fragment having amino acids 27-36 of SEQ ID NO:3.
  • the fragment having amino acids 17-26 (containing K18 with a free epsilon amine) was combined with the fragment of amino acids 27-36 (with the ivDde protected K28).
  • the resulting amino acid sequence having amino acids 17-36 was combined with the fragment comprising amino acids 1-16 in forming a synthetic peptide comprising the amino acid sequence of SEQ ID NO:3.
  • the synthetic peptide (SEQ ID NO:3) was deprotected to remove protecting groups trt, Boc, and tBu used in standard solid phase synthesis as described in more detail in Example 1 herein (while K28 remains chemically protected); decarboxylated; and then purified using reverse-phase high performance liquid chromatography.
  • the isolated HIV gp41 -derived peptide was then used for coupling to a polymer site-specifically to the free epsilon amine of K18 of SEQ ID NO:3.
  • mPEG succinimidyl propionate (“mPEG -SPA”) was chosen as the exemplary polymer to conjugate to T20 (SEQ ID NO:3).
  • T20 (SEQ ID NO:3) with ivDde on epsilon amine group of K28 (1 .7 mg, 4.4 ⁇ mol) was dissolved in DMF (0.5 ml).
  • DIEA (20 ⁇ l) was added to the reaction, and then added was mPEG-SPA (average molecular weight, 5000 daltons ("5K"); 50 mg, 10 ⁇ mol) in DMF (1ml).
  • the mixture was stirred at room temperature and the reaction is monitored by HPLC until the PEGylation was completed.
  • hydrazine 45 ⁇ l was added to the reaction to reach 3% (v/v) of hydrazine in reaction mixture.
  • the desired conjugate a substantially homogeneous conjugate comprised of 5K-PEG-T20 at K18 was obtained as fluffy white solid (10.4mg) after lyophilization.
  • the alpha amine of the N-terminal amino acid of SEQ ID NO:1 was not acetylated, but instead was protected with an Fmoc group.
  • the process of synthetic peptide synthesis and conjugation to polymer was performed as provided in this Example 3.
  • the resultant conjugate comprised a substantially homogeneous conjugate comprised of 5K-PEG-T20 at K18, except that the T20 (SEQ ID NO:3) of the conjugate contained a free alpha amine at the N-terminal amino acid (Y).
  • EXAMPLE 4 Illustrated in this example are: (a) a method determining the antiviral activity of substantially homogeneous conjugates produced according to the present invention; and (b) the need for a site-specific chemical modification according to the present invention to produce a substantially homogeneous conjugate comprised of polymer covalentiy coupled to HIV gp41 -derived peptide.
  • a site-specific chemical modification according to the present invention to produce a substantially homogeneous conjugate comprised of polymer covalentiy coupled to HIV gp41 -derived peptide.
  • antiviral activity e.g., one measure being the ability to inhibit transmission of HIV to a target cell
  • an in vitro assay which has been shown, by data generated using synthetic peptides derived from either of the HR regions of HIV gp41 , to be predictive of antiviral activity observed in vivo. More particularly, antiviral activity observed using an in vitro infectivity assay ("Magi-CCR5 infectivity assay"; see, e.g., U.S. Patent No. 6,258,782) has been shown to reasonably correlate to antiviral activity observed in vivo for the same HIV gp41 -derived peptides.
  • Magi-CCR5 infectivity assay see, e.g., U.S. Patent No. 6,258,782
  • T20 SEQ ID NO:3
  • T1249 SEQ. ID NO:96
  • the infectivity assays score for reduction of infectious virus titer employing the indicator cell lines MAGI or the CCR5 expressing derivative cMAGI. Both cell lines exploit the ability of HIV-1 tat to transactivate the expression of a ⁇ -galactosidase reporter gene driven by the HIV-LTR.
  • the ⁇ -gal reporter has been modified to localize in the nucleus and can be detected with the X-gal substrate as intense nuclear staining within a few days of infection.
  • the number of stained nuclei can thus be interpreted as equal to the number of infectious virions in the challenge inoculum if there is only one round of infection prior to staining.
  • Infected cells are enumerated using a CCD-imager and both primary and laboratory adapted isolates show a linear relationship between virus input and the number of infected cells visualized by the imager.
  • Vn/No 0.5
  • IC50 is defined as the dilution resulting in a 50% reduction in infectious virus titer).
  • the substantially homogeneous conjugates tested for antiviral activity were diluted into various concentrations, and tested in duplicate or triplicate against an HIV inoculum adjusted to yield approximately 1500-2000 infected cells/well of a 48 well microtiter plate.
  • the substantially homogeneous conjugate (in the respective dilution) was added to the cMAGI or MAGI cells, followed by the virus inocula; and 24 hours later, an inhibitor of infection and cell-cell fusion (e.g., T20) is added to prevent secondary rounds of HIV infection and cell-cell virus spread.
  • an inhibitor of infection and cell-cell fusion e.g., T20
  • the cells were cultured for 2 more days, and then fixed and stained with the X-gal substrate to detect HIV-infected cells.
  • the number of infected cells for each control and substantially homogeneous conjugate dilution was determined with the CCD-imager, and then the IC50 and IC90 is calculated (typically expressed in ⁇ g/ml).
  • IC50 and IC90 is calculated (typically expressed in ⁇ g/ml).
  • several substantially homogeneous conjugates separately produced by the methods described herein, were analyzed for antiviral activity as shown in Table 1 , and are identified as follows.
  • Conjugate A is a synthetic peptide having the amino acid sequence of SEQ ID ⁇ O:3 having a 2K PEG site-specifically conjugated to the N-terminal amine (hence, the side chain amines of both K18 and K28 were chemically protected during synthesis).
  • Conjugate B is a synthetic peptide having the amino acid sequence of SEQ ID NO:3 having a 2K PEG site-specifically conjugated to K18 (thus, the N-terminal amine and the side chain amine of K28 were chemically protected during synthesis).
  • Conjugate C is a synthetic peptide having the amino acid sequence of SEQ ID NO:3 having a 2K PEG site-specifically conjugated to K28 (thus, the N-terminal amine and the side chain amine of K18 were chemically protected during synthesis).
  • Conjugate D is a synthetic peptide having the amino acid sequence of SEQ ID NO:3 having a 5K PEG site-specifically conjugated to the N-terminal amine (hence, the side chain amines of both K18 and K28 were chemically protected during synthesis).
  • Conjugate E is a synthetic peptide having the amino acid sequence of SEQ ID NO:3 having a 5K PEG site-specifically conjugated to K18 (thus, the N-terminal amine and the side chain amine of K28 were chemically protected during synthesis).
  • Conjugate F is a synthetic peptide having the amino acid sequence of SEQ ID NO:3 having a 5K PEG site- specifically conjugated to K28 (thus, the N-terminal amine and the side chain amine of K18 were chemically protected during synthesis).
  • antiviral activity of the synthetic peptide is best preserved when a polymer of average size of 2K (2,000 daltons) is conjugated to the N-terminal amine versus at K18 (with at least 5 fold less activity) or K28 (with at least 10 fold less activity).
  • antiviral activity of the synthetic peptide is best preserved when a 5K polymer is conjugated to the N-terminal amine versus at K18 (about 5 fold less activity) or K28 (about 7 fold less activity).
  • the method of site specific chemical modification according to the present invention may be used to site-specifically couple a polymer to a selected amino acid of the synthetic peptide in producing a substantially homogeneous conjugate of peptide-polymer conjugate having a desired level of biological activity (e.g., in this example, desired antiviral activity is measured by having an IC50 of less than 0.02 ⁇ g/ml) (e.g., "Conjugate A" of Table 1 ) while avoiding producing a synthetic peptide-polymer conjugate of multiple species that lacks the desired level of biological activity using standard PEGylation (e.g., a mixture of "Conjugate A" and "Conjugate B” and "Conjugate C” of Table 1 ).
  • desired level of biological activity e.g., in this example, desired antiviral activity is measured by having an IC50 of less than 0.02 ⁇ g/ml) (e.g., "Conjugate A" of Table 1 ) while avoiding producing a synthetic
  • EXAMPLE 5 illustrated are additional embodiments of the method for site- specific chemical modification of an HIV gp41 -derived peptide, wherein incorporated into a synthetic peptide during synthesis are: one or more amino acids having its side chain amine blocked by a chemical protecting agent from subsequent chemical reactivity with an amine-reactive functionality; and one or more amino acids having an amine (e.g., selected from the group consisting of N-terminal alpha amine, one or more epsilon amines, and a combination thereof) unprotected, and free for chemical reactivity with an amine-reactive functionality.
  • an amine e.g., selected from the group consisting of N-terminal alpha amine, one or more epsilon amines, and a combination thereof
  • the resultant isolated HIV gp41 -derived is then conjugated to a polymer in producing a substantially homogeneous conjugate comprised of polymer and HIV gp-41 derived peptide.
  • a fragment condensation approach to synthesizing an HIV gp41 -derived peptide it is apparent to one skilled in the art that this approach of fragment assembly can be used, and has been used for some of the synthetic peptides having a sequence shown in SEQ. ID. NOs: 3-175, in the methods according to the present invention.
  • typically 3 fragments are synthesized (see, e.g., FIG.
  • an "N-terminal fragment” (usually comprised of between 10 and 20 of the amino acids of the amino terminus of the synthetic peptide), a "C- terminal fragment” (usually comprised of between 10 and 20 of the amino acids of the carboxy terminus of the synthetic peptide), and a "middle fragment” (usually comprised of between 10 and 20 of the amino acids found between the N-terminal fragment and the C- terminal fragment, in the synthetic peptide) which are then assembled to produce the complete synthetic peptide.
  • T1249 SEQ ID NO:96 was used in the method of site-specific chemical modification according to the present invention.
  • the synthetic peptide was synthesized by the fragment condensation approach using 3 fragments: an N-terminal fragment comprising amino acids 1-12 and containing a lysine at amino acid position 7 ("K7"), and an acetylated N-terminal amino acid; a middle fragment comprising amino acids 13 to 26 and containing a lysine at amino acid position 21 ("K21"); and a C- terminal fragment comprising amino acids 27 to 36 and containing a lysine at amino acid position 28 ("K28”) and a lysine at amino acid position 31 (“K31”) (the amino acid position numbering corresponding to the respective positions in SEQ ID NO:96; i.e., in the assembled synthetic peptide).
  • a number of isolated HIV gp41 -derived peptides according to the present invention were separately produced: (a) a synthetic peptide having the amino acid sequence of SEQ ID NO:96 with a chemical protecting agent on K7, K21 , K28, and K31 (leaving only the N-terminal amine free for subsequent conjugation to polymer); (b) a synthetic peptide having the amino acid sequence of SEQ ID NO:96 with a chemical protecting agent on the N-terminal amine, K21 , K28, and K31 (leaving only K7 side chain amine free for subsequent conjugation to polymer); (c) a synthetic peptide having the amino acid sequence of SEQ ID NO:96 with a chemical protecting agent on the N-terminal amine, K7, K28, and K31 (leaving only K21 side chain amine free for subsequent conjugation to polymer); (d) a synthetic peptide having the amino acid sequence of SEQ ID NO:96 with a chemical protecting agent on the N-terminal amine,
  • substantially homogeneous conjugates were separately produced from these isolated HIV gp41- derived peptides having an amino acid sequence of SEQ ID NO:96 and the method for specific chemical modification described herein, using different sizes of PEG ranging from an average of 2K daltons ("2K”) to an average of 20K daltons (“20K”).
  • Table 2 shows antiviral activity of some of these substantially homogeneous conjugates, identified as follows.
  • Conjugate A is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 2K PEG site-specifically conjugated to the N- terminal amine (hence, the side chain amines of K7, K21 , K28, and K31 were chemically protected during synthesis).
  • Conjugate B is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 2K PEG site-specifically conjugated to K7 (thus, the N-terminal amine, and the side chain amines of K21 , K28, arid K31 were chemically protected during synthesis).
  • Conjugate C is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 2K PEG site-specifically conjugated to K21 (thus, the N-terminal amine, and the side chain amines of K7, K28, and K31 were chemically protected during synthesis).
  • Conjugate D is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 2K PEG site-specifically conjugated to K28 (thus, the N-terminal amine, and the side chain amines of K7, K21 , and K31 were chemically protected during synthesis).
  • Conjugate E is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 2K PEG site-specifically conjugated to K31 (thus, the N-terminal amine, and the side chain amines of K7, K21 , and K28 were chemically protected during synthesis).
  • Conjugate F is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 5K PEG site-specifically conjugated to the N- terminal amine.
  • Conjugate G is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 5K PEG site-specifically conjugated to K7.
  • Conjugate H is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 5K PEG site-specifically conjugated to K21.
  • Conjugate I is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 5K PEG site-specifically conjugated to K28.
  • Conjugate J is a synthetic peptide having the amino acid sequence of SEQ ID NO:96 having a 5K PEG site-specifically conjugated to K31.
  • the method of site-specific chemical modification according to the present invention may be used to site-specifically couple a polymer to a selected amino acid of the synthetic peptide in producing a substantially homogeneous conjugate having a desired level of biological activity (e.g., in this example, the desired antiviral activity is measured by having an IC50 of less than 0.01 ⁇ g/ml) (e.g., "Conjugate A", "Conjugate B", and “Conjugate D” of Table 2) while avoiding producing a synthetic peptide-polymer conjugate of multiple species that lacks such desired level of biological activity using standard PEGylation (e.g., a mixture of the Conjugates A-E of Table 2).
  • EXAMPLE 6 In another example, a synthetic peptide having an amino acid sequence of SEQ ID NO:174 was used in the method of site-specific chemical modification according to the present invention.
  • the synthetic peptide containing a lysine at amino acid position 30 (“K30") and a lysine at amino acid position 39 (“K39"; the C-terminal amino acid; the amino acid position numbering corresponding to the position in SEQ ID NO:174) was synthesized by linear synthesis with a chemical protecting agent on the N-terminal amine of the N-terminal amino acid, and on the side chain amine of K30 (leaving only the K39 side chain amine free for subsequent conjugation to polymer).
  • Substantially homogeneous conjugates were separately produced from this isolated HIV gp41- derived peptide using a polymer having an average size of 2K, a polymer having an average size of 5K, and a polymer having an average size of 20K.
  • the synthetic peptide alone (not conjugated to a polymer) has a desired level of biological activity (e.g., antiviral activity as measured by having an IC50 of less than or equal to 0.02 ⁇ g/ml), whereas a substantially homogeneous conjugate synthetic having a polymer of average size of 2K had biological activity about equal to 0.02 ⁇ g/ml.
  • Substantially homogeneous conjugates having a polymer of average size of either 5K or 20K had biological activity much greater than 0.1 ⁇ g/ml (i.e., outside the range of desired biological activity for this example).
  • EXAMPLE 7 The present invention provides for substantially homogeneous conjugates comprised of an HIV gp41 -derived peptide to which is coupled site-specifically a polymer ("synthetic peptide-polymer conjugates"). Antiviral activity of such synthetic peptide- polymer conjugates can be utilized in a method for inhibiting transmission of HIV to a target cell, comprising adding to the virus and cell an amount of synthetic peptide-polymer conjugate according to the present invention effective to inhibit infection of the cell by HIV, and more preferably, to inhibit HIV-mediated fusion between the virus and the target cell.
  • This method may be used to treat HIV-infected individuals (therapeutically) or to treat individuals newly exposed to or at high risk of exposure (e.g., through drug usage or high risk sexual behavior) to HIV (prophylactically).
  • an effective amount of synthetic peptide-polymer conjugate would be a dose sufficient (by itself and/or in conjunction with a regimen of doses) to reduce HIV viral load in the individual being treated.
  • there are several standard methods for measuring HIV viral load which include, but are not limited to, by quantitative cultures of peripheral blood mononuclear cells and by plasma HIV RNA measurements.
  • the synthetic peptide-polymer conjugates of the invention can be administered in a single administration, intermittently, periodically, or continuously, as can be determined by a medical practitioner, such as by monitoring viral load.
  • a medical practitioner such as by monitoring viral load.
  • the synthetic peptide-polymer conjugate according to the present invention may be administered with a periodicity ranging from days to weeks or possibly longer.
  • a synthetic peptide-polymer conjugate according to the present invention may be used, in antiviral therapy, when used in combination or in a therapeutic regimen (e.g., when used simultaneously, or in a cycling on with one drug and cycling off with another) with other antiviral drugs used for treatment of HIV (e.g., including, but not limited to, other HIV entry inhibitors (e.g., CCR5 inhibitors, retrocyclin, and the like), HIV integrase inhibitors, reverse transcriptase inhibitors (e.g., nucleoside or nonnucleoside), protease inhibitors, viral-specific transcription inhibitors, viral processing inhibitors, HIV maturation inhibitors, inhibitors of uridine phosphorylating enzyme, HIV vaccines, and the like, as well known in the art.
  • HIV entry inhibitors e.g., CCR5 inhibitors, retrocyclin, and the like
  • HIV integrase inhibitors e.g., reverse transcriptase inhibitors (e.g., nucleo
  • one or more antiviral agents may be combined in therapy with synthetic peptide-polymer conjugate according to the present invention, thus increasing the efficacy of the therapy, and lessening the ability of the virus to become resistant to the antiviral drugs.
  • Such combinations may be prepared from effective amounts of antiviral agents (useful in treating of HIV infection) currently approved or approved in the future, which include, but are not limited to, abacavir, AZT, delaviridine, ddC, ddl, efavirenz, FTC, (+) and (-) FTC, Reverset, GS 840, HBY097, 3TC, nevirapine, d4T, FLT, emtricitabine, amprenivir, CGP-73547, CGP-61755, DMP-450, indinavir, nelfinavir, PNU-140690, ritonavir, saquinavir, telinavir, tenofovir, adefovir, atazanavir, lopinavir, VX 478, PRO-542, and betulin and dihydrobetulin derivatives (e.g., PA-457).
  • antiviral agents include, but are not limited to,
  • Effective dosages of these illustrative antiviral agents which may be used in combinations with synthetic peptide-polymer conjugate according to the present invention, are known in the art. Such combinations may include a number of antiviral agents that can be administered by one or more routes, sequentially or simultaneously, depending on the route of administration and desired pharmacological effect, as is apparent to one skilled in the art.
  • Effective dosages of a synthetic peptide-polymer conjugate of the invention to be administered may be determined through procedures well known to those in the art; e.g., by determining potency, biological half-life, bioavailability, and toxicity.
  • an effective synthetic peptide-polymer conjugate dosage range is determined by one skilled in the art using data from routine in vitro and in vivo studies well know to those skilled in the art.
  • in vitro infectivity assays of antiviral activity such as described herein, enables one skilled in the art to determine the mean inhibitory concentration (IC) of the synthetic peptide-polymer conjugate necessary to block some amount of viral infectivity (e.g., 50% inhibition, IC 50 ; or 90% inhibition, IC 0 ).
  • an exemplary dosage range of the synthetic peptide-polymer conjugate according to the present invention may range from no less than 0.1 ⁇ g/kg body weight and no more than 10 mg/kg body weight; preferably a dosage range of from about 0.1-100 ⁇ g/kg body weight; and more preferably, a dosage of between from about 10 mg to about 250 mg of synthetic peptide-polymer conjugate.
  • a synthetic peptide-polymer conjugate of the present invention may be administered to an individual by any means that enables the active agent to reach the target cells (cells that can be infected by HIV).
  • the synthetic peptide-polymer conjugates of this invention may be administered by any suitable technique, including oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, or subcutaneous injection or infusion, intradermal, or implant), nasal, pulmonary, vaginal, rectal, sublingual, or topical routes of administration, and can be formulated in dosage forms appropriate for each route of administration.
  • the specific route of administration will depend, e.g., on the medical history of the individual, including any perceived or anticipated side effects from such administration, and the formulation of conjugate being administered (e.g., the nature of the polymer and synthetic peptide of which the synthetic peptide-polymer conjugate comprises).
  • the administration is by injection (using, e.g., intravenous or subcutaneous means), but could also be by continuous infusion (using, e.g., slow- release devices or minipumps such as osmotic pumps, and the like).
  • a synthetic peptide-polymer conjugate according to the present invention may further comprise a pharmaceutically acceptable carrier; and may further depend on the formulation desired, site of delivery, the method of administration, the scheduling of administration, and other factors known to medical practitioners. »
  • a pharmaceutically acceptable carrier may further depend on the formulation desired, site of delivery, the method of administration, the scheduling of administration, and other factors known to medical practitioners. »

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé visant à produire une modification chimique spécifique de site d'un peptide dérivé de gp41 du VIH. Lors de la synthèse, un ou plusieurs groupes amine du peptide dérivé de gp41 du VIH sont choisis en vue d'être bloqués par un agent de protection chimique ; et un ou plusieurs groupes amine, sélectionnés en vue d'être non protégés, restent libres de réagir avec une fonctionnalité sensible aux amines. Le peptide obtenu peut servir à produire un conjugué sensiblement homogène, constitué du peptide dérivé de gp41 du VIH et d'un polymère, par le couplage covalent du polymère avec un ou plusieurs groupes amine libres (non protégés) du peptide.
PCT/US2005/007486 2004-03-15 2005-03-08 Modification chimique specifique de site de peptides derives de gp41 du vih WO2005089796A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05724921A EP1734994A1 (fr) 2004-03-15 2005-03-08 Modification chimique specifique de site de peptides derives de gp41 du vih
JP2007503945A JP2007529522A (ja) 2004-03-15 2005-03-08 ＨＩＶｇｐ４１由来ペプチドの部位特異的化学修飾
CA002556032A CA2556032A1 (fr) 2004-03-15 2005-03-08 Modification chimique specifique de site de peptides derives de gp41 du vih
IL177268A IL177268A0 (en) 2004-03-15 2006-08-03 Site -specific chemical modification of hiv gp41-derived peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55306304P 2004-03-15 2004-03-15
US60/553,063 2004-03-15

Publications (1)

Publication Number Publication Date
WO2005089796A1 true WO2005089796A1 (fr) 2005-09-29

Family

ID=34993445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/007486 WO2005089796A1 (fr) 2004-03-15 2005-03-08 Modification chimique specifique de site de peptides derives de gp41 du vih

Country Status (6)

Country Link
EP (1) EP1734994A1 (fr)
JP (1) JP2007529522A (fr)
CN (1) CN1929860A (fr)
CA (1) CA2556032A1 (fr)
IL (1) IL177268A0 (fr)
WO (1) WO2005089796A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089805A2 (fr) * 2004-03-15 2005-09-29 Nektar Therapeutics Al, Corporation Compositions a base de polymeres et conjugues d'inhibiteurs d'entree du vih
WO2007068163A1 (fr) * 2005-12-14 2007-06-21 Institute Of Biotechnology, The Academy Of Military Medical Sciences, Pla Peptides inhibiteurs de la fusion du vih et leur utilisation
EP1954302A2 (fr) * 2005-11-02 2008-08-13 Ambrx, Inc. Inhibiteurs de fusions polypeptidiques biosynthetiques
EP1989220A2 (fr) * 2006-02-02 2008-11-12 Trimeris, Inc. Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
EP2139526A1 (fr) * 2007-04-03 2010-01-06 Trimeris, Inc. Nouvelles formulations destinées à l'application de thérapies peptidiques antivirales
WO2011095989A3 (fr) * 2010-02-04 2012-01-12 Matrix Laboratories Ltd Procédé amélioré pour préparer de l'enfuvirtide
CN104788548A (zh) * 2014-01-20 2015-07-22 中国人民解放军军事医学科学院毒物药物研究所 新型抗hiv感染多肽及其利用
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550290B1 (fr) * 2010-03-24 2015-12-02 Medical Research Council Méthode de modifier une lysine spécifique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US20020151473A1 (en) * 1996-11-06 2002-10-17 Braisted Andrew C. Constrained helical peptides and methods of making same

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089805A3 (fr) * 2004-03-15 2007-07-19 Nektar Therapeutics Al Corp Compositions a base de polymeres et conjugues d'inhibiteurs d'entree du vih
US9446139B2 (en) 2004-03-15 2016-09-20 Nektar Therapeutics Polymer-based compositions and conjugates of HIV entry inhibitors
WO2005089805A2 (fr) * 2004-03-15 2005-09-29 Nektar Therapeutics Al, Corporation Compositions a base de polymeres et conjugues d'inhibiteurs d'entree du vih
EP1954302A4 (fr) * 2005-11-02 2009-11-04 Ambrx Inc Inhibiteurs de fusions polypeptidiques biosynthetiques
EP1954302A2 (fr) * 2005-11-02 2008-08-13 Ambrx, Inc. Inhibiteurs de fusions polypeptidiques biosynthetiques
CN103965300A (zh) * 2005-11-02 2014-08-06 Ambrx公司 生物合成多肽融合抑制剂
WO2007068163A1 (fr) * 2005-12-14 2007-06-21 Institute Of Biotechnology, The Academy Of Military Medical Sciences, Pla Peptides inhibiteurs de la fusion du vih et leur utilisation
JP4682251B2 (ja) * 2006-02-02 2011-05-11 トリメリス，インコーポレーテッド 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
EP1989220A2 (fr) * 2006-02-02 2008-11-12 Trimeris, Inc. Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
EP1989220A4 (fr) * 2006-02-02 2009-05-06 Trimeris Inc Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
JP2009525051A (ja) * 2006-02-02 2009-07-09 トリメリス，インコーポレーテッド 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
US8034899B2 (en) 2006-02-02 2011-10-11 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
EP2139526A4 (fr) * 2007-04-03 2010-07-14 Trimeris Inc Nouvelles formulations destinées à l'application de thérapies peptidiques antivirales
EP2139526A1 (fr) * 2007-04-03 2010-01-06 Trimeris, Inc. Nouvelles formulations destinées à l'application de thérapies peptidiques antivirales
WO2011095989A3 (fr) * 2010-02-04 2012-01-12 Matrix Laboratories Ltd Procédé amélioré pour préparer de l'enfuvirtide
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
US10081657B2 (en) 2010-05-21 2018-09-25 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
US10844094B2 (en) 2010-05-21 2020-11-24 Technische Universität München Biosynthetic proline/alanine random coil polypeptides and their uses
CN104788548A (zh) * 2014-01-20 2015-07-22 中国人民解放军军事医学科学院毒物药物研究所 新型抗hiv感染多肽及其利用
WO2015106673A1 (fr) * 2014-01-20 2015-07-23 中国人民解放军军事医学科学院毒物药物研究所 Nouveau polypeptide résistant à l'infection au vih et applications associées
CN104788548B (zh) * 2014-01-20 2018-06-05 中国人民解放军军事医学科学院毒物药物研究所 新型抗hiv感染多肽及其利用

Also Published As

Publication number Publication date
IL177268A0 (en) 2006-12-10
EP1734994A1 (fr) 2006-12-27
JP2007529522A (ja) 2007-10-25
CN1929860A (zh) 2007-03-14
CA2556032A1 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
EP1989220B1 (fr) Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
WO2005089796A1 (fr) Modification chimique specifique de site de peptides derives de gp41 du vih
JP4805911B2 (ja) Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
EP4414377A1 (fr) Procédé d'optimisation d'inhibiteur de fusion membranaire virale, lipopeptide anti-coronavirus à large spectre et son utilisation
US20100016225A1 (en) CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY
EP1206272A1 (fr) Polypeptides hybrides possedant des proprietes pharmacocinetiques ameliorees
EP2139526A1 (fr) Nouvelles formulations destinées à l'application de thérapies peptidiques antivirales
WO2006105201A2 (fr) Conjugues constitues d'acide gras et de peptide derive du gp41 du vih
WO2021223422A1 (fr) Polypeptide anti-vih modifié avec un peg à poids moléculaire élevé, sa préparation et son utilisation
US20100261876A1 (en) Novel methods of synthesis for therapeutic antiviral peptides
AU2003270894B2 (en) Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
US6379679B1 (en) Multiple branch peptide construction
MXPA06009352A (es) Modificacion quimica especifica del sitio de peptidos derivados de gp 41 del vih
BRAY et al. Patent 2556032 Summary

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 177268

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2556032

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009352

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200580007348.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007503945

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3374/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005724921

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005724921

Country of ref document: EP